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Most in vivo studies on the conversion to insulin-producing cells with AAV carrying PDX1 gene are
performed in rodents. However, there is little information regarding Adeno-associated virus (AAV) car-
rying PDX1 gene transduced to human liver in vivo because accidental death caused by unpredicted
factors cannot be denied, such as the hypoglycemic agent troglitazone with hepatic failure.
Here we aim to conﬁrm insulin secretion from human liver transduced with AAV carrying PDX1 gene
in vivo and any secondary effect using a humanized liver mouse.
As the results, AAV2-PG succeeded to improve the hyperglycemia of STZ-induced diabetic humanized
liver mice. Then, the analysis of humanized liver mice revealed that the AAV2-PG was more transducible
to humanized liver area than to mouse liver area.
In conclusion, the humanized liver mouse model could be used to examine AAV transduction of human
hepatocytes in vivo and better predict clinical transduction efﬁciency than nonhumanized mice.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of diabetes mellitus appears to be increasing,
mainly in the United States, Africa, and Asia. Since World War II,
there has been a marked increase in diabetic patients in Japan
because of dramatic lifestyle changes. Accordingly, various antidi-
abetic drug therapies have been developed. Historically, diabetic
therapy was ﬁrst introduced with insulin in 1922 [1]. Japanese oral
hypoglycemic agents, tolbutamide [2], a sulfonylurea, was ﬁrst used
in 1957, and the biguanides [3] came into use in 1961. In the 1990s,
oral agents such as alpha-glucosidase inhibitors [3], glinides [4],
and thiaziridines [3] with various mechanisms of action were
available and were used depending on the condition of a patient.
Additionally, among the thiaziridines, troglitazone [5] and piogli-
tazone [6] were applied to medical treatment in 1997 and 1999,
respectively. However, troglitazone was discontinued in 2000
because an associated secondary effect of hepatic failure due to
troglitazone resulted in death [7]. This unfortunate effect ofo).
Inc. This is an open access article utroglitazone in humans could not be predicted by animal experi-
ments. In particular, the hepatic differences between humans and
rodents made it impossible to predict troglitazone-related acci-
dental death.
The humanized mouse has developed based on any immuno-
deﬁcient mice as NOD/Shi-scid IL2rgnull (NOG) [8], NOD/LtSz-scid
IL2rgnull [9], and BALB/c Rag2nullIL2rgnull [10], to improve the spe-
ciﬁc differences between humans and rodents. Reconstitution of
human hematopoietic [11] and immune systems [12] in immuno-
deﬁcient mouse strains was a major advance in the ﬁeld of hu-
manized mouse technologies. Meanwhile, the reconstitution of
human organs in the bodies of immunodeﬁcient mice has also been
promoted in the ﬁeld of tissue engineering. Hasegawa et al. suc-
ceeded in establishing mice with humanized livers, termed “hu-
manized liver mice.” [13] Additionally, it has been shown that
humanized liver mice are thalidomide sensitive although rodents
are originally thalidomide resistant [14]. These results demon-
strated that the humanized liver mice succeeded in acquiring the
same metabolism as humans in the human liver section recon-
stituted in the intra-peritoneum of the mice. Therefore, experi-
ments using mice with humanized livers could predict the results
in humans.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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attracted by the application of adeno-associated virus (AAV) vector
for human gene diabetic therapy [16]. AAV vectors are a promising
alternative gene transduction system and are based on the defec-
tive and nonpathogenic parvovirus AAV sero-type 2 (AAV2) [17].
Coupled with the ability to transduce both dividing and nondi-
viding cells, recent in vivo studies with AAV have resulted in efﬁ-
cient and long-term gene transfer in a variety of tissues, such as
muscle [18], central neurons [19], liver [20], and retina [21]. In
particular, liver cells have been converted to insulin-producing cells
with AAV carrying the PDX1 gene [15]. We also conﬁrmed that
human and rodent hepatocytes transfected with PDX1 gene
demonstrated insulin secretions in vitro [22]. However, the insulin
secretion from human hepatocytes introduced with PDX1 gene has
not yet been investigated in vivo despite the veriﬁcation in vitro
[22]. Meanwhile, human gene therapy using AAV has been applied
for clinical testing in Alzheimer's disease [23], Parkinson's disease
[24], and hemophilia B [25]. Therefore, we expected a signiﬁcant
outcome of human gene therapy in diabetes using AAV.
We hypothesized that AAV transduction to the humanized liver
mouse could predict the effect of human gene therapy. In this study,
we examined the AAV2 carrying PDX1 gene to human diabetes
using a humanized liver mouse model. The purpose of this study is
to conﬁrm the insulin secretions from human liver transduced the
AAV2 carrying PDX1 gene in vivo and the secondary effect in the
diabetic therapy. Little information about how AAV2 carrying PDX1
gene is transduced to human hepatocytes in vivo. The results ob-
tained from the humanized liver mouse model in this study could
be signiﬁcant for clinical application of AAV because it is equivalent
to prove a result in humans in vivo.
2. Materials and methods
2.1. Mice
TK-NOG mice were obtained from the Central Institute for
Experimental Animals (CIEA). Mice were maintained under a 12-h
lightedark cycle and were provided with Rodent Laboratory Chow
(CLEA Japan, Tokyo, Japan) and water ad libitum. To induce diabetes,
mice received an intraperitoneal injection of STZ (180 mg STZ/kg
body weight) resuspended in 0.1 M citrate buffer (pH 4.5). Fasting
(2e3 h) blood glucose concentrations were monitored by an
automatic blood glucosemeter (Arkray, Kyoto, Japan). Then, the
STZ-induced diabetic mice were treated with AAV intrasplenic (isp)
or intravenous (iv) injection.
This study was approved by the Animal Committee of the CIEA
(Permit No.14050A).
2.2. Constructions of transgene to produce AAVs
The AAV packaging plasmids were constructed using pAAV-MCS
Expression Vector (Cat No. VPK-410, Cell Biolabs, Inc., San Diego, CA,
USA). PDX1-(2A)-GFP fragment or GFP gene was inserted to SalI-
BglII site in pAAV-MCS Expression Vector (Fig.1A). Insulin induction
from these plasmids was conﬁrmed by previous report [22].
2.3. AAV production
Packaging of AAV2 capsid used HEK 293 cells (Cat No. AAV-100,
Cell Biolabs, Inc.). The cells were maintained at 37 C in a humidi-
ﬁed environment containing 5% CO2 in Dulbecco's Modiﬁed Eagle's
Medium (Cat No. 044-29765, Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) with 10% fetal bovine serum (HyClone Laboratories,
South Logan, UT). AAV2-PDX1-(2A)-GFP and AAV2-GFP were pro-
duced using a standard triple transfection method employing atransgene vector, the pAAV-RC2 vector (Cat No. 340201, Cell Bio-
labs, Inc.), and the pHelper vector (Cat No. 340202, Cell Biolabs, Inc.)
with FuGENE HD and were packaged into AAV serotype 2 capsids
(AAV2). Subsequently, the AAVs were puriﬁed using the ViraBind™
AAV Puriﬁcation Kit (Cat No. VPK-140, Cell Biolabs, Inc.) and titered
using the QuickTiter™ AAV Quantitation Kit (Cat No. VPK-145, Cell
Biolabs, Inc.) according to the manufacturer's protocols.2.4. RNA preparation and PCR
Total RNAwas extracted from heart, lung, liver, pancreas, spleen,
and kidney of TK-NOG mice and human liver mice using TRizol
reagent (Invitrogen, Grand Island, NY) following themanufacturer's
instruction. RNA (liver, 500 ng; pancreas, 100 ng) was then reverse
transcribed using superscriptIII (Invitrogen). PCR was carried out
with Gﬂex (Cat No. R060A, Takara Bio Inc., Shiga, Japan) and speciﬁc
primers for insulin (forward: 50-CAGCCCTTAGTGACCAGCTA-30 and
reverse: 50 -ATGCTGGTGCAGCACTGATC-30, 348 bp), glucokinase
(forward: 50-CCCAGAAGGCTCAGAAGTTG-30 and reverse: 50
-CATGTACTTTCCGCCAATGA-30, 699 bp), and GAPDH (forward: 50-
AACGGGAAGCCCATCACC-30 and reverse: 50 -CAGCCTTGGCAGCAC-
CAG-30, 441 bp) according to the manufacturer's instructions. The
PCR ampliﬁcation was carried out for 25 cycles, consisting of 95 C
for 30 s; 60 C (insulin1), 62.5 C (glucokinase), or 68 C (GAPDH)
for 30e40 s; and 72 C for 5 min in 20 ml of reaction mixture. The
PCR products were subjected to 3% agarose gel electrophoresis and
visualized by Gel Red staining (Cat No. WK04529795, Wako, Osaka,
Japan).2.5. Glucose tolerance test
Seven days after transduction of AAV2, mice were fasted for 6 h
before the study. They then were challenged with an oral glucose
dose of 1.0 mg/g body weight. Blood samples were taken from the
orbital sinus using a heparinized capillary tube at 0, 15, 30, 60, 90,
and 120 min after glucose administration, and blood glucose con-
centrations were measured using an automatic blood glucose
meter.2.6. Generation of humanized liver mice
Generation of humanized liver mouse was made according to
Hasegawa et al. [13].2.7. In vivo animal imaging
Spectral ﬂuorescence images were obtained using the IVIS
Spectrums (Caliper Life Sciences, Hopkinton, MA, USA).2.8. Immunohistochemistry
Sections of liver, ﬁxed in 10% buffered formalin and embedded
in parafﬁn, were mounted on silane-coated glass slides and stained
by polymer method. Sections were pretreated with 0.03% hydrogen
peroxide (H2O2) in methanol to block endogenous peroxidase ac-
tivity. The sections were incubated overnight (4 C) with rabbit
anti-GFP (Cat No. ab290, Abcam, Cambridge, UK), diluted 4000-
fold, followed by a 1-h incubation (room temperature) with the
simple-stain mouse MAX-PO(R) (Cat No. 414341, Nichirei Biosci-
ence Inc., Tokyo, Japan). The antigeneantibody reaction was visu-
alized by incubation in 0.05 M Tris-HCl (pH 7.6) containing 0.02%
3,30-diaminobenzidine and 0.005% H2O2. Immunostained sections
were counterstained with hematoxylin for visualization of nuclei.
Fig. 1. Localization of AAV2-PDX1-GFP and induced insulin expression in TK-NOG mice. (A) Constructions of transgene, AAV2-PDX1-GFP (AAV2-PG) or AAV2-GFP (AAV2-G), to
produce AAVs. (B) Conﬁrmation of AAV2-PDX1-GFP introduced to mouse liver. The brown in the right-hand picture represents the GFP-positive cells. Calibration bars in pictures of
immunohistochemistry analysis represent 100 mm. (C) Conﬁrmation of PDX1 expression included in AAV2-PD. (D) Conﬁrmation of gene expressions of insulin1, glucokinase, and
GAPDH in mouse heart, lung, liver, pancreas, spleen, and kidney introduced by AAV2-PG. The positive controls of insulin1 gene, glucokinase gene, and GAPDH gene were cDNA
extracted and synthesized from pancreas in TK-NOG mice.
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Total proteins from cells were extracted from the separated red
phase generated by TRIzol reagent extraction and washed with 2-
propanol and GuCl2. A total of 40 mg protein extract in 1% sodium
dodecyl sulfate solution were separated electrophoretically on 7%
polyacrylamide gels and blotted onto nitrocellulose membranes
(Hybond™ ECL™, AmershamPharmacia Biotech Inc., Piscataway, NJ,
USA). The membranes were incubated with primary antibodies,
followed by the ECL™ anti-rabbit immunoglobulin, horseradish
peroxidase-linked F (ab0)2 fragment (Cat No. NA9340V, GE Health-
careUK, Ltd., LittleChalfont, Buckinghamshire,UK). The intensities of
the separatedbandswerequantiﬁedusing the ImageQuant LAS4000
Mini (GEHealthcare UK, Ltd.). Antibodies used in this study included
anti-human PDX1 (28 kDa; Cat No. ab72324, Abcam, Cambridge, UK;
1:200), anti-GFP (27 kDa; Cat No. ab290, Abcam; 1:1500), and anti-
mouse/human GAPDH (37 kDa; Cat No. ab9485, Abcam; 1:2500).2.10. Immunoﬂuorescence analysis
Frozen section of caudate lobe of liver was washed with PBS
and blocked with either 10% normal goat serum (Cat No. H0809,
Nichirei Bioscience Inc., Tokyo, Japan) or 10% normal rabbit serum
(Cat No. H1212, Nichirei Bioscience Inc.) for 30 min. The liver was
treated with biotin-labeled human HLA (Cat No. 13-9769-80,
eBioscience, San Diego, CA, USA) as the primary antibody, fol-
lowed by APC-streptavidin (Cat No. 554067, BD Biosciences, San
Jose, CA, USA) as the secondary antibody. Detection of GFP did not
require antibodies because it was expressed via AAV2 carrying
GFP gene. Finally, the liver was stained and mounted with 40,6-
diamidino-2-phenyl-indole (ImmunoSelect Antifading Mounting
Medium DAPI, Cat No. SCR-38448, Dianova, Hamburg, Germany).
The liver was analyzed using a ﬂuorescence microscope (AXIO
Imager, M1, Cat No. 18355, Carl Zeiss International, Barcelona,
Spain).
Fig. 2. Investigations of conditions (injection route, dose, and promoter region to
drive AAV2-PDX1-GFP) to improve hyperglycemia in STZ-induced diabetic mice. (A)
Investigation of efﬁcient injection route to improve hyperglycemia from STZ-induced
diabetic mice receiving AAV2-PG or AAV2-G by intrasplenic (isp) or intravenous in-
jection. (B) Effect of AAV2-PG on impaired glucose tolerance in STZ-induced diabetic
mice. (C) Recovery of glucose-responsive insulin secretion by AAV2-PG isp injection in
STZ-induced diabetic mice.
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Forty-two days after transduction of AAV2, the hepatocytes
were isolated from the liver except caudate lobe through the two-
step collagenase perfusion [26] of the liver samples as described
previously [27]. The hepatocytes (6  106) were collected and
washed with PBS. After removing the supernatant by centrifuga-
tion, the hepatocytes were blocked with 10% normal rabbit serum
(Cat No. H1212, Nichirei Bioscience Inc., Tokyo, Japan) for 15 min.
After further removal of the supernatant by centrifugal separation,
the hepatocytes were treated with biotin-labeled human leukocyte
antigen (HLA) antibody (Cat No. A80-229A, Bethyl, Tokyo, Japan) as
the primary antibody, followed by APC-streptavidin (Cat No.
554067, BD Biosciences) as the secondary antibody. After replacing
the cells in PBS, the hepatocytes were analyzed by FACS Canto (BD
Biosciences). Detection of GFP did not require antibodies because it
was expressed via plasmids. Data were recorded using the BD FACS
Diva Software program (BD Biosciences) and analyzed using the
Flowjo program (Tree Star Inc., Ashland, OR, USA).
3. Results
3.1. Basic study on inhibitory effect of AAV2-PDX1-GFP transduction
on hyperglycemia in STZ-induced diabetic TK-NOG mice
To conﬁrm the expression and localization of PDX1 as indicated
by GFP expression from the injected AAV2-PG carrying human
cytomegalovirus (CMV) promoter, the internal organs in STZ-
induced diabetic mice treated with AAV2-PG isp or iv injection
were investigated. The mouse injected isp with the AAV2-PG
demonstrated GFP expression in the liver (Fig. 1B). GFP expres-
sion in the mouse injected iv with AAV2-PG was comparatively
weak. Transduction of AAV2-PG induced PDX1 protein expression
in the liver (Fig. 1C). Insulin1 mRNA was detected in the liver but
not detected in other organs (Fig. 1D, upper). Additionally,
expression of the glucokinase gene alsowas detected in liver only of
STZ-induced diabetic mice treated with AAV2-PG isp (Fig. 1D,
middle). GAPDH mRNA was detected in all organs of STZ-induced
diabetic mice treated with AAV2-PG isp (Fig. 1D, lower).
To examine whether hepatic insulin production induced by
AAV2-PG is capable of controlling blood glucose concentrations in
diabetic nonhumanized liver TK-NOG mice, we injected TK-NOG
mice with 180 mg/kg STZ and AAV2-PG or AAV2-G. Blood glucose
concentrations were decreased by AAV2-PG isp injection of
7  1010VC, which was a more pronounced change compared with
the effects of AAV2-G isp injection (Fig. 2A). Furthermore, 21 days
after the AAV2 injection, we administered an oral glucose tolerance
test. In STZ-induced diabetic mice, hyperglycemia was improved by
treatment with AAV2-PG compared with treatment with AAV2-G
(Fig. 2B). Serum insulin concentrations before and after glucose
challenge in mice injected with AAV2-PG recovered from hypo-
secretion (Fig. 2C). However, an iv injection of AAV2-PGwith titer of
7 1010VC could not decrease high concentrations of blood glucose
induced by STZ in TK-NOG mice; AAV2-PG iv injection with titer of
1.5  1011VC was needed to improve hyperglycemia.
3.2. Analysis of humanized liver mouse transduced AAV2-PG
To estimate the effectiveness of AAV2-PG carrying CMV pro-
moter in humans, the human liver mouse injected with AAV2-PG
was analyzed. The mouse injected isp with AAV2-PG demon-
strated GFP expression in liver (Fig. 3A). Expression of AAV2-PG in
the reconstituted humanized liver area was conﬁrmed by immu-
noﬂuorescent observations (Fig. 3B). Additionally, FCM analysis
showed that the Pdx1 and GFP genes were more prevalent inhumanized liver areas compared with mouse liver areas by AAV2
transduction (Fig. 3C). Based on HLA immunohistological analysis,
the chimeric rate of liver in humanized liver mouse was 27.3% in
this study.
Nonfasting blood glucose concentrations of the humanized liver
mouse with STZ-induced diabetes were decreased by AAV2-PG isp
injection, which was a more pronounced change compared with
the effects of AAV2-G isp injection (Fig. 3D). At this time, impaired
glucose tolerance and glucose-responsive mouse insulin secretion
(Fig. 3E) were recovered by AAV2-PG isp injection in the humanized
liver mouse with STZ-induced diabetes. Additionally, human insu-
lin induced by AAV2-PG isp injection also showed glucose response
(Fig. 3F).
Fig. 3. Effects of AAV2-PDX1-GFP intrasplenic (isp) injection on humanized liver mouse. (A) Localizations of AAV2-PG injected to STZ-induced diabetic humanized liver mouse.
(B) Immunoﬂuorescent observations of the humanized liver infected with AAV2-PG. The calibration bars represent 100 mm. (C) FMC analysis of GFP in STZ-induced diabetic hu-
manized liver mouse infected with AAV2-PG. (D) Blood glucose concentrations of STZ-induced diabetic humanized liver mice receiving AAV2-PG or AAV2-G by isp injection. Effect of
AAV2-PG on impaired glucose tolerance in STZ-induced diabetic humanized liver mouse. (E) Recovery of glucose-responsive mouse insulin secretion by AAV2-PG isp injection in
STZ-induced diabetic humanized liver mouse. (F) Induction of glucose-responsive human insulin secretion by AAV2-PG isp injection in STZ-induced diabetic humanized liver
mouse.
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After basic research on the transduction of AAV2-PG in this
study, we performed the transduction of AAV2-PG to a humanized
liver mouse to attempt the prediction of outcomes in humans.
Several results and problems were revealed in this study.
First, we investigated the effective injection route and promoter
region for gene therapy using AAV.We determined the isp injection
of 7  1010 VC/mouse consisting of AAV2-PG driven by CMV pro-
moter improved hyperglycemia in mice with STZ-induced diabetes.
However, iv injection of AAV2-PG driven by CMV promoter region
required 1.5  1011 VC/mouse to improve hyperglycemia. These
doses of AAV approximately correspond to previous studies [28].
GFP expression conﬁrmed the presence of the PDX1 gene in liver
by in vivo bioﬂuorescent imaging analysis as shown in Figs. 1B and
3A. The expression of the PDX1 gene in liver led the ectopic insulin
secretions (Fig. 1D), which could have an effect on insulin receptors
in liver and muscles through blood and inhibit hyperglycemia in
STZ-induced diabetic TK-NOG mice. Additionally, the insulin from
livers of STZ-induced diabetic mice injected with AAV2-PG would
be able to acquire glucose response because the expression of
glucokinase gene related to glucose response [22]. Therefore, the
isp injection of AAV2-PG driven by CMV promoter was shown to be
an effective procedure for gene therapy targeting liver.
AAV2-PG was more effectively transduced to human hepato-
cytes than mouse hepatocytes in an STZ-induced diabetic human-
ized liver mouse. Stable expression of transgene by AAV
transduction in primates continued for a signiﬁcantly longer period
compared with rodents [29]. Additionally, a seroepidemiologic
study showed that AAV2 was endemic to humans [30]. Therefore,
human livers might be transduced using AAV as effectively as ro-
dent livers.
Additionally, there is another problem with the clinical appli-
cation of AAV in humans. AAV-gene therapy is not yet effective for
human because 40%e70% of humans have acquired AAV antibodies,
which counteracts AAV delivery [31]. Furthermore, isp injection
during laparotomy is believed to be difﬁcult for humans using AAV-
gene therapy. Mimuro et al. succeeded in delivering AAV8 to
monkey liver with an insertion into the hepatic portal vein from the
jejunoileal vein using a micro-balloon catheter [32]. Their injection
method is expected to be applicable to human therapy by inserting
the catheter from the femoral vein and should solve the counter-
action by AAV antibodies to AAV-gene therapy.
Therefore, we hypothesize that isp injection of AAV2-PG would
effectively treat human diabetes without a secondary effect,
judging from the transduction of PDX1 gene in a humanized liver
mouse model. Additionally, this study demonstrated that the hu-
manized liver mouse could be used to examine AAV transduction of
human hepatocytes in vivo. Then, we believe that the humanized
liver mouse may become a better model to predict clinical trans-
duction efﬁciencies than nonhumanized mouse.
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